All In Biotech

Drug Trial Radar · NCT04242446

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 505 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

505

Actual

Start

Feb 19, 2020

Primary completion

Apr 7, 2022

Study completion Feb 19, 2023

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Jan 27, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)

Conditions

  • Hidradenitis Suppurativa

Interventions

  • BimekizumabDrug

    Subjects will receive bimekizumab at pre-specified time-points.

  • PlaceboOther

    Subjects will receive placebo at pre-specified time-points during the Initial Treatment Period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16Time frame: Week 16

Locations

88 sites in 15 countries. Site status is shown where the registry gives one.

  • Hs0003 50140

    Birmingham, Alabama

  • Hs0003 50175

    Phoenix, Arizona

  • Hs0003 50161

    Los Angeles, California

  • Hs0003 50220

    San Diego, California

  • Hs0003 50205

    North Miami Beach, Florida

  • Hs0003 50153

    Ormond Beach, Florida

  • Hs0003 50141

    Tampa, Florida

  • Hs0003 50210

    Atlanta, Georgia

  • Hs0003 50280

    Watkinsville, Georgia

  • Hs0003 50425

    Murray, Kentucky

  • Hs0003 50198

    Beverly, Massachusetts

  • Hs0003 50146

    Boston, Massachusetts

  • Hs0003 50194

    Omaha, Nebraska

  • Hs0003 50208

    Las Vegas, Nevada

  • Hs0003 50137

    East Windsor, New Jersey

  • Hs0003 50235

    New York, New York

  • Hs0003 50151

    Chapel Hill, North Carolina

  • Hs0003 50177

    Cincinnati, Ohio

  • Hs0003 50138

    Columbus, Ohio

  • Hs0003 50204

    Tulsa, Oklahoma

  • Hs0003 50147

    Hershey, Pennsylvania

  • Hs0003 50008

    Johnston, Rhode Island

  • Hs0003 50180

    Providence, Rhode Island

  • Hs0003 50142

    Nashville, Tennessee

  • Hs0003 50201

    Arlington, Texas

  • Hs0003 50166

    Dallas, Texas

  • Hs0003 50149

    San Antonio, Texas

  • Hs0003 50270

    Seattle, Washington

  • Hs0003 30015

    Campbelltown, Australia

  • Hs0003 30016

    Carlton, Australia

  • Hs0003 30011

    East Melbourne, Australia

  • Hs0003 30017

    Kogarah, Australia

  • Hs0003 30012

    Woolloongabba, Australia

  • Hs0003 40004

    Brussels, Belgium

  • Hs0003 40121

    Brussels, Belgium

  • Hs0003 40002

    Leuven, Belgium

  • Hs0003 40060

    Liège, Belgium

  • Hs0003 50233

    Barrie, Canada

  • Hs0003 50190

    Richmond Hill, Canada

  • Hs0003 50192

    Saskatoon, Canada

Showing 40 of 88 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.